Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

30.80 -0.77 (-2.45%)
Streaming Delayed Price Updated: 3:07 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript ↗
CEO Rosen targets casdatifan as $5B to $10B drug with no frontline competition. 
Via The Motley Fool
Topics Earnings
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Q2 Earnings Call Highlights ↗
Arcus Biosciences (NYSE:RCUS) outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter... 
Via MarketBeat
Topics Earnings
Arcus Biosciences (NYSE:RCUS) Beats Q2 Estimates and Advances Casdatifan Pipeline ↗
Via Chartmill
Arcus Biosciences (NYSE:RCUS) Q1 Loss Narrows But Revenues Miss Estimates; Focus Shifts to Kidney Cancer Drug Casdatifan ↗
Via Chartmill
Arcus Biosciences Inc (NYSE:RCUS) Reports Mixed Q4 2025 Results as Pipeline Strategy Pivots to Casdatifan ↗
Via Chartmill
News headline image
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
From Summit Therapeutics
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
News headline image
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run ↗
This sale was executed under a Rule 10b5-1 plan following a 203% one-year surge. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Arcus Biosciences
Via Business Wire
News headline image
Arcus (RCUS) Q1 2026 Earnings Call Transcript ↗
Arcus (RCUS) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Arcus (RCUS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.